Henry Schein Announces Appointment of Three New Members to the Company’s Executive Management Committee

Rhea-AI Summary

Henry Schein, Inc. (NASDAQ: HSIC) appoints three new members to its Executive Management Committee, including Co-CEOs of the Global Oral Reconstruction Group and the CEO of the Healthcare Specialties Group. The new appointments aim to enhance the Company's leadership team and advance its strategic plan for higher growth and margin specialty products and services.

Joining Henry Schein’s EMC are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group

MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today announced that it has appointed three new members to the Company’s Executive Management Committee (EMC) – Steve Boggan and Bianka Wilson, who were recently named Co-CEOs of the Company’s Global Oral Reconstruction Group (GORG), and Tom Popeck, CEO of the Company’s Healthcare Specialties Group (HSG).

Bianka Wilson, Co-Chief Executive Officer, Global Oral Reconstruction Group, Henry Schein, Inc. (Photo: Business Wire)

GORG includes the Company's comprehensive portfolio of premium value and value implant lines and a full range of biomaterial products. HSG includes a range of company-owned manufacturing brands in the high-growth endodontic, orthodontic, and orthopedic markets.

“We are delighted to welcome three strong and proven leaders to the Henry Schein Executive Management Committee,” said Stanley Bergman, Chairman and Chief Executive Officer of Henry Schein, Inc. “Steve, Bianka, and Tom have each demonstrated vision and commitment in inspiring and leading our teams to excellence in a quickly changing global healthcare marketplace. Our senior leadership team will benefit greatly from the added perspectives of these seasoned professionals.”

The GORG and HSG businesses are central to advancing the Company’s BOLD+1 strategic plan, in particular the building of higher-growth and higher-margin specialty products and services offerings that complement our distribution, software, and value-added businesses. Together, the Company is leveraging these businesses to broaden and deepen relationships with customers.

Mr. Boggan joined Henry Schein in 2013 with the Company’s acquisition of BioHorizons, which he joined as a start-up in 1995 and has led as President and CEO since 1999. As Co-CEO of GORG, Mr. Boggan will lead commercial operations in North and South America and the Middle East as well as global marketing.

Ms. Wilson joined Henry Schein in 2018 after a successful 25-year career in finance and consulting. Prior to Henry Schein, she served as Group CFO of Ascom Holding AG, a Swiss public company in the medical communication technology sector and, prior to that, as Advisory and Global Account Lead Partner at KPMG. Ms. Wilson had been serving as Chief Financial Officer of GORG and, as Co-CEO, she will lead strategy, finance, and human resources as well as the group’s business in Europe and APAC.

Mr. Popeck joined Henry Schein in 2019 with more than 20 years of sales leadership and general management experience, including extensive experience in the medical device sector. Prior to joining Henry Schein, he spent over two decades leading businesses in orthopedics and industrial manufacturing, including spending 11 years at Stryker, where he held various leadership roles, including leading Stryker’s Foot & Ankle business unit as Vice President and General Manager. In 2023, he was promoted to President of Henry Schein’s Healthcare Specialties Group.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410230713/en/

Investors:

Ronald N. South

Senior Vice President and Chief Financial Officer

ronald.south@henryschein.com

(631) 845-2802

Graham Stanley

Vice President, Investor Relations and Strategic Financial Project Officer

graham.stanley@henryschein.com

(631) 843-5963

Media:

Ann Marie Gothard

Vice President, Global Corporate Media Relations

annmarie.gothard@henryschein.com

(631) 390-8169

Source: Henry Schein, Inc.

FAQ

Who are the new members appointed to Henry Schein's Executive Management Committee?

The new members appointed to Henry Schein's Executive Management Committee are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group.

What is the ticker symbol for Henry Schein, Inc.?

The ticker symbol for Henry Schein, Inc. is HSIC.

What are the key businesses included in the Global Oral Reconstruction Group (GORG) and Healthcare Specialties Group (HSG)?

GORG includes the Company's comprehensive portfolio of premium value and value implant lines and a full range of biomaterial products, while HSG includes a range of company-owned manufacturing brands in the high-growth endodontic, orthodontic, and orthopedic markets.

When did Mr. Boggan join Henry Schein and what are his responsibilities as Co-CEO of GORG?

Mr. Boggan joined Henry Schein in 2013 and as Co-CEO of GORG, he leads commercial operations in North and South America, the Middle East, and global marketing.

What is Ms. Wilson's background and role at Henry Schein as Co-CEO of GORG?

Ms. Wilson joined Henry Schein in 2018 with a 25-year career in finance and consulting. As Co-CEO of GORG, she leads strategy, finance, human resources, and the group's business in Europe and APAC.

When did Mr. Popeck join Henry Schein and what is his experience in the medical device sector?

Mr. Popeck joined Henry Schein in 2019 with over 20 years of sales leadership and general management experience in the medical device sector, including leading businesses in orthopedics and industrial manufacturing.